Trials / Recruiting
RecruitingNCT05116579
Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- Male
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
To evaluate the application value of customized ctDNA monitoring in efficacy assessment and prediction during PARPi treatment
Detailed description
This clinical study is an open-label, single-center, observational study to evaluate the application value of customized ctDNA monitoring in efficacy assessment and prediction during PARPi treatment in mCRPC patients. A total of 30 participants with second-line treatment failure will be registered in this study. Whole blood collection will be conducted during the treatment for ctDNA detection, homologous recombination repair (HRR) genes testing, personalized panel customization and whole exome sequencing.
Conditions
Timeline
- Start date
- 2021-10-31
- Primary completion
- 2023-03-31
- Completion
- 2025-08-31
- First posted
- 2021-11-11
- Last updated
- 2024-09-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05116579. Inclusion in this directory is not an endorsement.